GlassScriptPhysician profile
Paul G Degregorio
NPI 1508850827
$2,486.50
in general payments reported to CMS, 2019-2025
22 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $262 · 2021: $177 · 2022: $89.01 · 2023: $339 · 2024: $722 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.57 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $575.19 | 2019-2025 | Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $273.92 | 2019-2021 | |
| Astellas Pharma US INC | $256.08 | 2023-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $181.95 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $170.43 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $159.77 | 2022-2025 | Miebo, Amvisc, Vyzulta |
| Oyster Point Pharma, INC. | $99.19 | 2023-2024 | Tyrvaya, Ryzumvi |
| Genentech USA, INC. | $94.82 | 2019-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $92.39 | 2023-2025 | Syfovre |
| Janssen Pharmaceuticals, INC | $91.61 | 2024 | Xarelto |
| Alimera Sciences, INC. | $75.11 | 2023-2024 | Yutiq, Iluvien |
| Allergan, INC. | $64.16 | 2019-2021 | |
| Optovue, INC. | $63.61 | 2019 | |
| Abbvie INC. | $63.60 | 2023-2025 | Alphagan P, Lumigan, Vuity |
| Glaukos Corporation | $46.58 | 2024 | Ce-Marked Kxla System, Photrexa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $46.24 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $29.69 | 2020-2021 | |
| Dompe US, INC. | $26.20 | 2024 | Oxervate |
| Alcon Vision LLC | $21.54 | 2022 | |
| Shire North American Group INC | $19.37 | 2019 | |
| Thea Pharma INC. | $19.36 | 2023 | |
| Omeros Corporation | $15.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Degregorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.